Loading…
Teva Pharmaceutical Industries Limited is projected to rise to $38.89 by 2027, a +23% move from its current price of $31.67. TEVA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $31.07 | $31.67 | $32.28 | 0.00% |
| Aug 1 | $30.82 | $31.67 | $32.54 | -0.01% |
| Aug 2 | $30.63 | $31.67 | $32.74 | -0.01% |
| Aug 3 | $30.47 | $31.67 | $32.91 | -0.01% |
| Aug 4 | $30.33 | $31.67 | $33.05 | -0.01% |
| Aug 5 | $30.21 | $31.66 | $33.19 | -0.02% |
| Aug 6 | $30.10 | $31.66 | $33.31 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.10 | $31.66 | $33.31 | -0.02% |
| Week 2 | $29.46 | $31.66 | $34.02 | -0.04% |
| Week 3 | $28.99 | $31.65 | $34.56 | -0.06% |
| Week 4 | $28.59 | $31.65 | $35.03 | -0.08% |
| Week 5 | $28.24 | $31.64 | $35.45 | -0.10% |
| Week 6 | $27.93 | $31.63 | $35.83 | -0.12% |
| Week 7 | $27.65 | $31.63 | $36.18 | -0.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Teva is a healthcare stock with a current price of $31.56 and a market cap of $36.75B. It ranks 397 by market capitalization.
The forecast outlook shows the average price edging higher from the 2026 level, with 2026 average priced at $31.56 and rising in successive years.
Longer-term milestones include a 2030 average of $58.43 (85.2% ROI), a 2040 average of $127.35 (303.5% ROI), and a 2050 average of $285.10 (803.4% ROI). Sentiment shifts to bullish from 2027 onward, reflecting an upside trajectory over the multi-year horizon.
A major floor 14.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.8% below — buyers have tended to step in here.
The nearest ceiling, 11.4% above — a clean break opens room to run.
A major ceiling 17.8% above — clearing it would confirm fresh momentum.
Key TEVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TEVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $30.91 | Buy | $31.05 | Buy |
| MA 10 | $31.32 | Buy | $31.43 | Buy |
| MA 20 | $32.49 | Sell | $32.06 | Sell |
| MA 50 | $33.32 | Sell | $32.74 | Sell |
| MA 100 | $32.46 | Sell | $32.31 | Sell |
| MA 200 | $30.43 | Buy | $29.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.03 | Neutral |
| Stoch RSI (14) | 59.61 | Neutral |
| CCI (20) | -78.20 | Neutral |
| Williams %R (14) | -69.90 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -6.10 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 30.10 | Neutral |
| TRIX (15) | -0.25 | Sell |
| Awesome (5,34) | -1.95 | Sell |
| Ultimate (7,14,28) | 35.39 | Neutral |
| Momentum (10) | -1.10 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 30.66 | Buy |
| ADX (14) | 15.13 | Neutral |
| ATR (14) | 0.61 | Info |
The near-term technical picture is bullish, with RSI14 at 40 and a price structure that aligns with upside potential. The 50-day simple moving average sits at $34.07 while the 200-day simple moving average sits at $29.97, indicating the stock is trading above a longer-term trend but near-term pressure near resistance.
Support is identified at $31.48 and resistance at $35.29. The 30-day range runs from a low of $27.99 to a high of $35.59, offering a recent window of price activity around the current level. Annualized volatility is 30%, underscoring sizeable, but not extreme, price movement potential in the weeks ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.35 | $31.67 | $40.27 | 0% | Neutral | |
| $31.84 | $38.89 | $49.65 | +23% | Bullish | |
| $39.26 | $48.87 | $64.14 | +54% | Bullish | |
| $43.09 | $54.50 | $73.09 | +72% | Bullish | |
| $46.92 | $60.16 | $82.17 | +90% | Bullish | |
| $52.49 | $68.14 | $94.58 | +115% | Bullish | |
| $52.91 | $69.49 | $97.84 | +119% | Bullish | |
| $56.92 | $75.56 | $107.80 | +139% | Bullish | |
| $64.56 | $86.57 | $125.02 | +173% | Bullish | |
| $72.67 | $98.39 | $143.70 | +211% | Bullish | |
| $98.45 | $139.17 | $213.18 | +339% | Bullish | |
| $203.76 | $309.47 | $508.67 | +877% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.35 | $31.67 | $37.00 | +0.00% |
| August 2026 | $26.78 | $31.25 | $37.19 | -1.31% |
| September 2026 | $26.92 | $31.59 | $37.94 | +1.07% |
| October 2026 | $27.68 | $32.63 | $39.48 | +3.31% |
| November 2026 | $27.74 | $32.82 | $39.95 | +0.58% |
| December 2026 | $27.71 | $32.91 | $40.27 | +0.25% |
Click any year to see its month-by-month TEVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TEVA to range from $28.35 to $40.27 through 2026. The $31.67 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The TEVA price prediction for 2027 points to an average of $38.89 (low $31.84, high $49.65) — a potential gain of +23% on today's $31.67. Momentum favours further upside here.
In 2028, TEVA is projected to trade between $39.26 and $64.14, averaging $48.87 — a potential gain of +54% from today's $31.67. That is up +26% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Teva Pharmaceutical Industries Limited's 2029 outlook centres on $54.50, within a $43.09 to $73.09 range. That is up +12% on the projected 2028 average. That marks a +72% change versus current levels. Momentum favours further upside here.
By 2030, TEVA could reach as high as $82.17, with a base case around $60.16 and support toward $46.92 — roughly +90% from $31.67. Buyers look set to stay in control over this stretch.
Expect TEVA to range from $52.49 to $94.58 through 2031. The $68.14 average target implies a +115% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The TEVA price prediction for 2032 points to an average of $69.49 (low $52.91, high $97.84) — a potential gain of +119% on today's $31.67. Buyers look set to stay in control over this stretch.
In 2033, TEVA is projected to trade between $56.92 and $107.80, averaging $75.56 — a potential gain of +139% from today's $31.67. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Teva Pharmaceutical Industries Limited's 2034 outlook centres on $86.57, within a $64.56 to $125.02 range. That is up +15% on the projected 2033 average. That marks a +173% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, TEVA could reach as high as $143.70, with a base case around $98.39 and support toward $72.67 — roughly +211% from $31.67. Momentum favours further upside here.
Expect TEVA to range from $98.45 to $213.18 through 2040. The $139.17 average target implies a +339% move from current prices. That is up +41% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The TEVA price prediction for 2050 points to an average of $309.47 (low $203.76, high $508.67) — a potential gain of +877% on today's $31.67. Momentum favours further upside here.
Investing $1,000 in TEVA today (≈ 31.575624 TEVA) could be worth
$9,771.79
+$8,771.79 (+877%) by 2050 · US Dollar
Based on the average projected TEVA price of $309.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TEVAwould be worth at today's price.
$1,000 invested in TEVA on Jul 28, 2025 (≈ 60.569351 TEVA) would be worth
$1,918.23
+$918.23 (+91.8%) today · 1.92× · US Dollar
Based on a TEVA entry price of $16.51 vs. today's $31.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31 | $1,021.61 | +2.2% |
| 1 month ago | $33.21 | $953.63 | -4.6% |
| 3 months ago | $31.62 | $1,001.58 | +0.2% |
| 6 months ago | $33.21 | $953.63 | -4.6% |
| 1 year ago | $16.51 | $1,918.23 | +91.8% |
| All time (5.0y) ago | $9.85 | $3,215.23 | +221.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TEVA forecast.
Our base-case forecast reaches $63.00 around 2031.
Implied market cap at $63.00: $73.36B
The multi-year forecast shows a clear path of upside, with 2026 at an average of $31.56 and rising to stronger gains in later years. The 2027 average is $38.70 and the 2028 average is $47.11, with 2029 at $53.12 and 2030 at $58.43, all carrying bullish sentiment.
Beyond 2030, the forecast envisions continued gains: 2031 average $64.74, 2032 average $66.44, 2033 average $71.71, 2034 average $81.16, and 2035 average $92.98, all marked bullish.
The long-term horizon highlights dramatic upside: 2040 average $127.35 (303.5% ROI) and 2050 average $285.10 (803.4% ROI), both with bullish sentiment. These figures are estimates and not guaranteed, and actual results may differ.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $58.43, with a min of $45.65 and a max of $79.64; ROI is projected at 85.2% and sentiment is BULLISH.
The forecast indicates a path of rising averages from 2026 ($31.56) through 2035 ($92.98) and beyond, with bullish sentiment from 2027 onward and strong long-term upside (2040 avg $127.35; 2050 avg $285.10). These are estimates and not guaranteed.
The forecast shows a max of $194.24 in 2040 and an average of $127.35 in 2040, indicating the possibility of surpassing $100 by that period. Earlier years show smaller levels, but 2040 provides a clear above-$100 scenario.
The 30-day range is $27.99 to $35.59.
Teva Pharmaceutical Industries Limited Community Discussion
0Share your Teva Pharmaceutical Industries Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.